Platelet-rich plasma (PRP) for osteoarthritis (OA) of the knee
Osteoarthritis (OA) is the most common chronic joint disorder, and it causes detrimental effects on the quality of life and functional status. These are characterized by progressively occurring cartilage destruction, osteophyte formation, and subchondral sclerosis1, 2). The histopathological findings of OA show that homeostasis between the destruction and repair mechanisms of the joint cartilage is disturbed by the increased expression of inflammatory reaction . This causes degradation of the joints along with the insufficiency in the synthesis of growth factors and anti-inflammatory cytokines leading to pain, stiffness and swelling
Other
Osteoarthritis, also called degenerative joint disease, is the most common type of joint disease and is one of the 10 most disabling conditions in developed nations. It is characterized by the progressive erosion of articular cartilage and inflammatory cells. The promising therapeutic potential and regenerative properties of platelet-rich plasma (PRP) have rapidly led to its widespread clinical use in musculoskeletal injury and disease. Although the basic scientific rationale surrounding PRP products is compelling, the clinical application has outpaced the research. Objective. The purpose of this report is to examine the current concepts around the clinical application of PRP in OR in the knee
